Curr Treat Options Neurol:帕金森综合症视觉障碍的治疗

2018-07-01 cuiguizhong MedSci原创

美国马里兰大学医学院神经病学系的Savitt J和马里兰大学医学院眼科的Mathews M近日在Curr Treat Options Neurol发表了一篇文章,他们讨论了帕金森病(PD)和其他神经退行性疾病的视觉障碍。主要通过病理解剖来强调实际的治疗效果,可以有针对性的选择治疗方案,包括药物治疗、物理治疗以及光学辅助治疗。

美国马里兰大学医学院神经病学系的Savitt J和马里兰大学医学院眼科的Mathews M近日在Curr Treat Options Neurol发表了一篇文章,他们讨论了帕金森病(PD)和其他神经退行性疾病的视觉障碍。主要通过病理解剖来强调实际的治疗效果,可以有针对性的选择治疗方案,包括药物治疗、物理治疗以及光学辅助治疗。

现在人们对帕金森病和其他类似疾病的视觉发病原因有了更清楚的认识。现在有一种专门用于治疗PD幻觉的新药物可供使用。同时,人们对眼科医生在照顾这些患者中发挥的重要作用有了更多的了解。最后,作者指出,在治疗帕金森病和帕金森氏综合征的视觉障碍方面还没有得到满足。

更好地理解帕金森相关的视觉障碍和可用的治疗方案,对于优化患者安全和提高生活质量是非常重要的。其中这些视力障碍表现在包括阅读、走动和驾驶在内的许多常见活动中出现困难。由于视力受损更容易造成跌倒和受伤,导致早期丧失独立性。对这些问题的认识,作者认为,患者教育、眼科护理、特定治疗、物理治疗和职业治疗等对于最大限度地提高这些患者的生活质量是至关重要的。

原文出处:

Savitt, J. and M. Mathews, Treatment of Visual Disorders in Parkinson Disease. Curr Treat Options Neurol, 2018. 20(8): p. 30.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000484, encodeId=cdff2000484bb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 06 23:17:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056913, encodeId=99e6205691398, content=<a href='/topic/show?id=74dd48539f1' target=_blank style='color:#2F92EE;'>#帕金森综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48539, encryptionId=74dd48539f1, topicName=帕金森综合症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 16 22:17:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796267, encodeId=5a251e9626769, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Jan 28 21:17:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661282, encodeId=3bdb166128250, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sun Sep 30 08:17:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481102, encodeId=4726148110241, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue Jul 03 11:17:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328698, encodeId=9031328698e1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon Jul 02 09:49:33 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2019-05-06 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000484, encodeId=cdff2000484bb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 06 23:17:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056913, encodeId=99e6205691398, content=<a href='/topic/show?id=74dd48539f1' target=_blank style='color:#2F92EE;'>#帕金森综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48539, encryptionId=74dd48539f1, topicName=帕金森综合症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 16 22:17:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796267, encodeId=5a251e9626769, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Jan 28 21:17:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661282, encodeId=3bdb166128250, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sun Sep 30 08:17:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481102, encodeId=4726148110241, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue Jul 03 11:17:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328698, encodeId=9031328698e1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon Jul 02 09:49:33 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000484, encodeId=cdff2000484bb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 06 23:17:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056913, encodeId=99e6205691398, content=<a href='/topic/show?id=74dd48539f1' target=_blank style='color:#2F92EE;'>#帕金森综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48539, encryptionId=74dd48539f1, topicName=帕金森综合症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 16 22:17:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796267, encodeId=5a251e9626769, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Jan 28 21:17:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661282, encodeId=3bdb166128250, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sun Sep 30 08:17:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481102, encodeId=4726148110241, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue Jul 03 11:17:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328698, encodeId=9031328698e1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon Jul 02 09:49:33 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2000484, encodeId=cdff2000484bb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 06 23:17:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056913, encodeId=99e6205691398, content=<a href='/topic/show?id=74dd48539f1' target=_blank style='color:#2F92EE;'>#帕金森综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48539, encryptionId=74dd48539f1, topicName=帕金森综合症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 16 22:17:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796267, encodeId=5a251e9626769, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Jan 28 21:17:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661282, encodeId=3bdb166128250, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sun Sep 30 08:17:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481102, encodeId=4726148110241, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue Jul 03 11:17:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328698, encodeId=9031328698e1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon Jul 02 09:49:33 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2000484, encodeId=cdff2000484bb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 06 23:17:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056913, encodeId=99e6205691398, content=<a href='/topic/show?id=74dd48539f1' target=_blank style='color:#2F92EE;'>#帕金森综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48539, encryptionId=74dd48539f1, topicName=帕金森综合症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 16 22:17:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796267, encodeId=5a251e9626769, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Jan 28 21:17:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661282, encodeId=3bdb166128250, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sun Sep 30 08:17:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481102, encodeId=4726148110241, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue Jul 03 11:17:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328698, encodeId=9031328698e1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon Jul 02 09:49:33 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-07-03 zywlvao
  6. [GetPortalCommentsPageByObjectIdResponse(id=2000484, encodeId=cdff2000484bb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 06 23:17:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056913, encodeId=99e6205691398, content=<a href='/topic/show?id=74dd48539f1' target=_blank style='color:#2F92EE;'>#帕金森综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48539, encryptionId=74dd48539f1, topicName=帕金森综合症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 16 22:17:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796267, encodeId=5a251e9626769, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Jan 28 21:17:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661282, encodeId=3bdb166128250, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sun Sep 30 08:17:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481102, encodeId=4726148110241, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue Jul 03 11:17:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328698, encodeId=9031328698e1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon Jul 02 09:49:33 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-07-02 一天没事干

    很好的学习机会

    0

相关资讯

Eric Bennett教授:泛素-蛋白酶体系统可能是ALS和PD、癌症治愈的希望

据加州大学生物科学部刊登的学术文章称,该校细胞与发育生物学部教授Eric Bennett带领的Bennett 实验室正在用综合的生化学方法和细胞生物学方法研究泛素-蛋白酶体系统(UPS)。UPS被生物学界喻为细胞的废物管理系统,是细胞的质量控制系统,人类一旦了解并参与UPS的作用机理,很多疑难杂症,诸如肌萎缩侧索硬化症(ALS)、帕金森综合症(PD)、癌症都将被治愈。 英文阅读: Assist